EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 161 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $56,000 | -32.5% | 2,115 | +12.7% | 0.00% | 0.0% |
Q2 2022 | $83,000 | +2.5% | 1,877 | +14.7% | 0.00% | 0.0% |
Q1 2022 | $81,000 | +2.5% | 1,637 | +5.5% | 0.00% | 0.0% |
Q4 2021 | $79,000 | -8.1% | 1,552 | +1.0% | 0.00% | 0.0% |
Q3 2021 | $86,000 | +21.1% | 1,537 | -7.3% | 0.00% | 0.0% |
Q2 2021 | $71,000 | +9.2% | 1,658 | +7.1% | 0.00% | 0.0% |
Q1 2021 | $65,000 | -4.4% | 1,548 | +6.5% | 0.00% | 0.0% |
Q4 2020 | $68,000 | +6.2% | 1,453 | -3.3% | 0.00% | 0.0% |
Q3 2020 | $64,000 | +166.7% | 1,503 | +205.5% | 0.00% | – |
Q2 2020 | $24,000 | +20.0% | 492 | +11.1% | 0.00% | – |
Q1 2020 | $20,000 | -9.1% | 443 | +22.7% | 0.00% | – |
Q4 2019 | $22,000 | +4.8% | 361 | -3.2% | 0.00% | – |
Q3 2019 | $21,000 | 0.0% | 373 | +0.5% | 0.00% | – |
Q2 2019 | $21,000 | +40.0% | 371 | +25.3% | 0.00% | – |
Q1 2019 | $15,000 | +36.4% | 296 | +7.6% | 0.00% | – |
Q4 2018 | $11,000 | -26.7% | 275 | +31.0% | 0.00% | – |
Q3 2018 | $15,000 | +650.0% | 210 | +577.4% | 0.00% | – |
Q2 2018 | $2,000 | – | 31 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |